FeesSafety
Pluang+

BioLineRx and Hemispherian report promising Phase 1/2a trial progress for GLIX1 in glioblastoma treatment

Market News
16 Nov 2026, 14:00 WIB
PRNewsWire
View Source
Bullish
BioLineRx and Hemispherian report promising Phase 1/2a trial progress for GLIX1 in glioblastoma treatment

BioLineRx and Hemispherian announced positive updates on GLIX1, a novel oral TET2 activator for glioblastoma, presented at the Society for Neuro-Oncology meeting. The ongoing Phase 1/2a trial has reached its fourth dosing cohort with no safety concerns and will include new patient groups to assess brain penetration and biological activity. Preclinical data show strong, dose-dependent tumor inhibition, including in temozolomide-resistant models, supporting GLIX1's potential as a new glioblastoma therapy. Results from the clinical trial are expected in the first half of 2027, which will guide further development.

BioLineRx and Hemispherian's clinical and preclinical updates on GLIX1 provide context for readers following health innovations. For readers following the health sector, here is Pluang's market snapshot as of Nov 16, 2026 18:12 WIB: out of 150 priced US health stocks, 66 rose and 50 fell. Notable movers include Humana Inc (HUM) at USD 463.97 with a +3.10% change, Guardant Health Inc (GH) at USD 147.01 with a -3.18% change, and Brookdale Senior Living Inc (BKD) at USD 8.85 with a -3.49% change. The most notable figure is Humana's 3.10% gain.

More News

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian has launched the Enterprise Good Samaritan Program to identify and notify companies about high-impact leaked credentials that could expose their systems to attackers. Using AI and expert analysis, the program traces leaks to affected orga...

Market News
Neutral
23 minutes ago
Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo Inc. has renewed its Normal Course Issuer Bid (NCIB), allowing it to repurchase up to 22.5 million common shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's strategy to retur...

Company Fundamentals
Bullish
23 minutes ago
Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo Inc. announced the renewal of its normal course issuer bid, allowing it to repurchase up to 22.5 million ordinary shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's ongoing c...

Company Fundamentals
Bullish
23 minutes ago
Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo plc and Curio Legacy Ventures announced a collaboration to supply recycled nuclear materials for mixed-oxide (MOX) fuel production at Newcleo's planned US fuel manufacturing facility. This partnership combines Curio's NuCycle recycling techno...

Market News
Bullish
1 hour ago
Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics announced a 38% year-over-year revenue increase for Q3 2026, driven by its IC Drone insulator-cleaning activities. The company expanded its IC Drone platform into Greece through a strategic collaboration with CRONOS, identifying potenti...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App